EP Patent

EP3873607B1 — Quinazolinyl-indazole derivatives and their use as inhibitors of human immunodeficiency virus replication

Assigned to ViiV Healthcare UK No 5 Ltd · Expires 2023-11-29 · 2y expired

What this patent protects

Patent listed against lenacapavir-sodium.

Drugs covered by this patent

lenacapavir-sodium (LENACAPAVIR SODIUM)

Patent Metadata

Patent number: EP3873607B1
Jurisdiction: EP
Classification: —
Expires: 2023-11-29
Drug substance claim: No
Drug product claim: No
Assignee: ViiV Healthcare UK No 5 Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.